ARTICLES LIST

 

Total Results: 16203

Media ID Source Name Media Type Language Media Name Media Description Keywords Keywords Link to Article
1387 National Cancer Institute Html en Breast Cancer Prevention (PDQ®)–Health Professional Version Risk factors for breast cancer are female sex and advancing age, inherited risk, breast density, obesity, alcohol consumption, and exposure to ionizing radiation. Interventions to prevent breast cancer include chemoprevention (e.g. SERMs, AIs), risk-reducing surgery (e.g. mastectomy, oophorectomy). Review the evidence on risk factors and interventions to prevent breast cancer in this expert-reviewed summary.
Surgical Adjuvant Breast0.484835
situ breast cancer0.497037
Breast Cancer Intervention0.493501
breast cancer trends0.484079
breast cancer deaths0.490132
radiation-associated breast cancer0.489257
Engl J Med0.493511
post-menopausal breast cancer0.480461
Breast Cancer Surveillance0.4815
breast cancer incidence.0.495634
treatment-related breast cancer0.489379
early-stage breast cancer0.507669
fatal breast cancer0.490061
ER-positive breast cancer0.490928
breast cancer prevention0.509672
Breast Cancer Collaborative0.483305
breast cancer patients0.502781
postmenopausal breast cancer0.486608
therapy-related breast cancer0.480826
breast cancer risk.0.512722
Natl Cancer Inst0.684414
-negative breast cancer0.484014
breast cancer death0.482095
invasive breast cancer0.614612
et al.0.488773
Swedish breast cancer0.480364
women0.553885
contralateral breast cancer0.510667
early breast cancer0.491581
age-specific breast cancer0.483209
breast cancer susceptibility0.482582
breast cancers0.487583
age-adjusted breast cancer0.485699
breast cancer rates0.491912
human breast cancer0.484504
tamoxifen breast cancer0.487689
Female Breast Cancer0.482581
postmenopausal women0.549947
breast cancer risk0.650399
International Breast Cancer0.494317
Abstract0.524687
breast cancer0.96573
breast cancer mortality0.521549
breast cancer cases0.492675
Breast Cancer Study0.481834
ER-negative breast cancer0.487382
breast cancer incidence0.616078
elevated breast cancer0.489604
Excess breast cancer0.489271
CLICK HERE
1503 National Cancer Institute Html en Ovarian Germ Cell Tumors Treatment (PDQ®)–Health Professional Version Expert-reviewed information summary about the treatment of ovarian germ cell tumors.
adjuvant chemotherapy0.587693
pure dysgerminoma0.480069
Oncology Group trials0.399123
endodermal sinus tumor0.426786
chemotherapy0.67435
PDQ cancer information0.453857
incompletely resected tumors0.456006
cancer information summary0.450698
high-dose chemotherapy0.414186
recurrent germ cell0.415503
durable remission0.43875
radiographic procedures0.437608
para-aortic lymph nodes0.495597
patients0.944817
intact ovary0.411146
Surgical resection0.432079
adjuvant therapy0.398709
higher stage tumors0.443399
total abdominal hysterectomy0.474933
Gynecologic Oncology Group0.490243
Endodermal sinus tumors0.452987
radiation therapy0.487845
immature teratoma0.464025
modern chemotherapeutic era0.398622
advanced stage dysgerminoma0.404048
ovarian germ cell0.413493
clinical examination0.424181
primary tumor.0.431827
residual masses0.43388
well-staged patients0.406144
fallopian tube0.401507
completely resected tumors0.468623
BEP combination chemotherapy0.509951
cisplatin-based adjuvant treatment.0.511465
maximal surgical debulking0.469791
adjuvant setting0.44443
endodermal sinus0.463622
Second-look surgery0.421726
disease0.413051
large tumors0.399492
mixed germ cell0.430258
combination chemotherapy0.637036
salvage therapy.0.435874
cisplatin-containing combination chemotherapy0.471327
stage IA tumors0.445257
germ cell tumors0.871083
stage0.462819
initial surgical procedure0.530199
Cisplatin-based combination chemotherapy0.476734
CLICK HERE
1504 National Cancer Institute Html en Carcinoma of Unknown Primary Treatment (PDQ®)–Health Professional Version Expert-reviewed information summary about the treatment of metastatic cancer that has spread from an unidentified primary tumor.
prostate cancer-specific tests0.758495
moderately differentiated tumors0.76812
primary breast cancer0.810157
CUP tumors0.744436
germ cell tumor0.900926
unguided clinical evaluation0.74246
primary tumor origin.0.829274
lung cancer0.758661
major primary adenocarcinomas0.79306
bone metastases0.787576
CUP0.964346
unguided radiographic studies0.740775
patients0.907112
poorly differentiated tumor0.786876
poor prognostic finding.0.745421
fine-needle aspiration biopsy0.740303
axillary metastasis0.759204
stage information section0.75285
primary site0.901386
primary malignancy0.785612
primary disease0.779121
lung metastases0.79491
primary sites0.766562
treatable primary cancers.0.775244
CUP patients0.753414
primary manifestation0.731878
special diagnostic pathology0.734268
Lymph node involvement0.737229
pancreatic cancer0.758796
Breast Cancer Treatment0.769987
different metastatic distribution0.743182
single study0.73541
complete blood cell0.762048
predominant bony distribution0.735381
midline germ cell0.743808
noncarcinoma cell type0.749494
breast cancer0.825399
certain clinical presentations0.748925
primary tumor0.992795
prostate cancer0.879535
supradiaphragmatic primary malignancy0.778764
significant prognostic importance0.741352
potential primary lesion0.812433
appropriate clinical evaluation0.754068
occult primary tumor0.820012
End Results data0.738986
common primary carcinomas0.811152
primary prostate cancer.0.808097
CLICK HERE
1533 National Cancer Institute Html en Cancell/Cantron/Protocel (PDQ®)–Health Professional Version Expert-reviewed information summary about the use of Cancell/Cantron/Protocel as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only.
peer-reviewed scientific journals0.623029
NCI Tumor Cell0.661367
cell lines0.687144
human cells0.635256
aerobic metabolism0.794285
bacterium P. cryptocides.0.62979
PDQ cancer information0.88904
cancer development.0.663979
vitro NCI-60 DTP0.62954
somewhat different explanations0.628856
Cancer Terms0.627276
principal manufacturers0.71541
certain damaging conditions0.634012
Topical skin application0.63342
substantial antitumor activity.0.625666
cancer information summary0.875855
breast cancer prevention0.656117
Tumor Cell Line0.74552
clinical drug research0.64982
Cancell/Cantron/Protocel0.841588
Investigational New Drug0.649141
cancerous cells0.717346
NCI’s PDQ0.624803
NCI PDQ cancer0.71862
residual aerobic metabolism0.655098
NCI Dictionary0.62162
unapproved new drug0.650693
numerous animal experiments0.621001
completely primitive state0.63055
Therapies Editorial Board0.638692
vivo situation0.631095
excretion—an unlikely situation0.620899
original manufacturer0.721066
cancer cells0.761265
damaged normal cells0.711253
critical point0.644689
reference citations0.63628
idealized conditions Cancell/Cantron/Protocel0.671023
adult-onset diabetes mellitus0.639765
additional biochemical reactions0.628258
cell line screen0.841075
National Cancer Institute0.793891
NCI human cancer0.696144
normal cells0.997775
chronic energy stress0.639389
Human Tumor Cell0.638074
cancer information summaries0.702185
artificial media0.635059
CLICK HERE
1586 National Cancer Institute Html en Vaginal Cancer Treatment (PDQ®)–Patient Version Expert-reviewed information summary about the treatment of vaginal cancer.
cell vaginal cancer0.360195
lymph node dissection0.326781
body0.312996
abnormal areas0.281727
PDQ cancer information0.334259
vaginal cancer0.760063
clinical trial search0.36299
clinical trials0.668187
cancer information summary0.310305
clinical trial0.454575
squamous cell cancer0.354582
Vaginal Cancer Treatment0.308045
Pap test0.272131
patients0.293377
IVB vaginal cancer0.318217
NCI PDQ cancer0.278314
malignant tumor cells0.275963
Treatment Option Overview0.274359
lymph nodes0.290946
radiation therapy0.589716
General information0.282628
general cancer information0.271401
treatment0.460915
abnormal cells0.349727
wide local excision0.321438
Recurrent vaginal cancer0.337303
new cancer treatments0.27048
NCI-supported cancer0.305828
cancer cells0.3346
vaginal intraepithelial neoplasia0.296856
Cancer Information Service0.272009
vaginal cancer spreads0.334927
squamous cell0.369952
stage ivb0.271421
treatment clinical trials0.293735
National Cancer Institute0.348129
tumor cells0.290691
new treatment0.303739
cervix0.280807
IVA vaginal cancer0.291708
external radiation therapy0.454541
cancer clinical trials0.3729
cells0.353506
stage0.310322
cancer information summaries0.270039
comprehensive cancer information0.270279
internal radiation therapy0.457186
Cervical Cancer Treatment0.289689
cancer0.911572
CLICK HERE
1770 National Cancer Institute Html es Prurito (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos acerca del prurito (picazón en la piel) como complicación del cáncer o su tratamiento. Se consideran los abordajes de manejo y tratamiento del prurito.
haemodialysis patients0.476654
Section XII0.477073
Rubenstein E0.559292
Sin embargo0.803552
Scientific American Medicine0.676981
categoría farmacológica medicamento0.526417
Am Acad Dermatol0.571569
Clin Res0.479277
Wolff K0.536775
Acad Dermatol Venereol0.493209
Farber EM0.55456
patients with atopic0.550773
Cancer Nursing0.471101
PDQ Prurito0.665745
Dermatol Venereol Leprol0.6251
with atopic dermatitis0.566467
toxina botulínica0.473345
reacciones cutáneas0.538217
patients with0.621762
chronic idiopathic0.533598
Pain Symptom Manage0.649291
neuropathic pruritus0.513717
Scientific American0.875762
Oncol Nurs Forum0.782558
Malignant cutaneous tumors0.546882
Dosis Comentarios Referencias0.53479
General Medicine0.52531
terminal cancer patient0.535978
All Free Clear0.515267
Dermatol Venereol0.632286
farmacológica medicamento dosis0.550466
Clinical aspects0.477546
Medicamento Dosis Comentarios0.541353
Acta Derm Venereol0.979711
Eisen AZ0.543793
New York0.832579
patients receiving0.483634
Yosipovitch G0.516371
mg diarios comenzar0.507465
Abel EA0.553787
Enterostomal Ther0.474722
sistema nervioso central0.522009
pruritus relief with0.489446
policitemia vera0.673444
Dermatol Ther0.602936
Fitzpatrick TB0.546636
Federman DD0.567864
Bernhard JD0.556935
chronic pruritus0.522206
CLICK HERE
1857 National Cancer Institute Html es Tratamiento del cáncer escamoso metastásico de cuello con tumor primario oculto (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos acerca del tratamiento del cáncer escamoso metastásico de cuello con tumor primario oculto.
ominosa situación0.323583
microscopic findings with0.340934
poorly differentiated tumors0.343157
cisplatin-based combination chemotherapy0.340177
unknown primary site0.370765
N)a aReproducción0.321827
Instituto Nacional0.378061
Radiat Oncol Biol0.947729
bUna designación0.320629
emission tomography with0.337851
Diagn Pathol0.32218
chemoradiotherapy using0.320607
solid tumors0.321716
Acta Cytol0.320567
Head Neck Surg0.377028
primary site0.383303
after excisional biopsy0.335976
metastases from0.417556
dysfunction following radiotherapy0.335828
carcinoma nasofaríngeo0.419271
Kahn HJ0.320427
paciente varón0.325653
cervical lymph0.356026
Recent progress0.321743
intensity-modulated radiotherapy0.356033
Cheung R0.361917
from unknown primary0.367172
National Cancer Institute0.343401
PDQ Tratamiento0.380147
nasopharyngeal carcinoma0.428219
Lombardi Comprehensive Cancer0.345987
Clin Oncol0.335468
unknown primary0.700357
Physician Data Query0.330819
enfermedad n20.320558
Oncol Biol Phys0.999042
enfermedad n10.322779
largo plazos0.351849
metastatic adenocarcinomas0.360803
unknown primary tumor0.440765
Induction chemotherapy with0.342645
Gray GF Jr0.331989
neck cancer0.546903
American Joint Committee0.331644
Reimann BE0.320391
Miyazaki I0.364645
AJCC Cancer Staging0.353491
squamous cell carcinoma0.742589
solitary metastatic neck0.365007
CLICK HERE
1954 National Cancer Institute Html es Tratamiento del mesotelioma maligno (PDQ®)–Versión para pacientes Resumen de información revisada por expertos acerca del tratamiento del cáncer del mesotelioma maligno.
siguientes procedimientos0.614487
estadio iv0.791187
Malignant Mesothelioma0.549358
estadio ii0.653957
estadios ia0.559097
vía oral0.54921
rayos x0.916803
estadio ib0.585037
enlace drugs approved0.58335
estadio ia0.583181
ondas sonoras0.565775
líquido anormales.ampliar biopsia0.679304
siguientes síntomas0.602559
National Cancer Institute0.545373
siguientes riesgos0.53912
siguientes tratamientos0.580411
quimioterapia intraperitoneal hipertérmica0.640252
detalles minúsculos0.572451
Instituto Nacional0.580849
PDQ Tratamiento0.591752
alta potencia0.560897
presente sección0.540992
partes distantes0.551484
Physician Data Query0.667975
siguientes sitios0.687794
pequeña incisión0.582002
ecografía ayuda0.565218
cuerpo llamada ecograma0.656058
siguientes pruebas0.740981
CLICK HERE
3879 National Cancer Institute Html es Extractos de muérdago (PDQ®)–Versión para pacientes Resumen de información revisada por expertos sobre el uso de los extractos de muérdago como tratamiento para personas con cáncer.
cuerpo frente0.413451
Centro Nacional0.449381
New Hampshire Avenue0.415853
cabo ensayos0.424385
Drug Administration0.409825
NCI Best Case0.428572
PDQ Extractos0.439937
Helixor A0.41291
datos bibliográficos pubmed0.416761
marcas comerciales eurixor0.426376
siguientes preguntas0.410006
productos botánicos0.410905
Polyerga Neu0.415135
solicitudes ind0.41359
cura lotodo0.415539
vitamina b0.413657
siguientes riesgos0.412404
Instituto Nacional0.532861
National Center0.412812
siguientes marcas0.416399
Salud Complementaria0.466538
idioma alemán0.413696
Visuals Online0.41151
complementarias revisa0.415619
Physician Data Query0.465832
Estados Unidos0.692378
mejores cuidados0.41274
libre uso0.41183
cabo estudios0.418615
Integrative Health0.413952
página manejo0.410784
¿El tratamiento0.420943
¿Los beneficios0.40989
juntos cam0.409184
respuesta corporal frente0.42523
Series Program0.409771
medicina complementaria0.946895
árbol hospedador0.450028
CLICK HERE
3899 National Cancer Institute Html en National Cancer Act of 1937 National Cancer Act of 1937, signed into law by President Franklin D. Roosevelt, created the National Cancer Institute.
general public0.367365
National Cancer Advisory0.528357
cancer control work0.436895
research projects0.391515
act0.566247
similar research0.476584
General its approval0.365736
federal government0.49191
Cancer Institute Act0.442221
appointed member0.370413
National Advisory Cancer0.52537
technical matters0.410467
prevention0.411559
human knowledge0.397925
diagnosis0.527183
non-communicable disease0.363394
Cancer Advisory Council0.437071
PUBLIC NO.0.367229
independent research institute0.437264
principal agency0.418501
similar research activities0.412381
treatment centers0.373224
National Cancer Act0.475787
treatment0.554492
valuable contributions0.393688
United States0.637137
methods0.412995
Institute consultation services0.410647
cause0.426942
training0.369834
Advisory Cancer Council0.524827
cancer research0.428314
private institutions0.416999
Franklin D. Roosevelt0.416988
Public Law0.367866
cancer experts0.38424
State health agencies0.402781
National Cancer Institute0.913007
official business0.397421
research institutions0.36768
Committee Report No.0.406179
approval0.369507
HR.7931. 75th Congress0.4075
acceptance conditional gifts0.395258
Cancer Investigations0.395678
Surgeon General0.940401
Public Health Service0.694963
75th congress0.416285
time0.374442
CLICK HERE

 

 

 

Terms of Use | Privacy Policy
©2017 ARCHES Technology. All Rights Reserved.